Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Source: SeekingAlpha
2025-07-18 09:30:11 ET
Background
Since its spin-off from Pfizer ( PFE ) in 2012, the New Jersey-based Zoetis Inc. ( ZTS ) has become the most dominant pharmaceutical company engaged in animal health. Approximately 2/3 rd of its revenue is derived from treatments for pets, and the other 1/3 rd from livestock. By a significant margin, they remain the largest player in this space....
Read the full article on Seeking Alpha
For further details see:
Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Ste Virbac Sa Ord
NASDAQ: VRBCF
VRBCF Trading
0.0% G/L:
$346 Last:
23 Volume:
$346 Open:
